Maral Skelsey
Dermatology · Washington, DCNPI 1699750315
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,711 of the $61,797 with a category attached, or 77.2%. Barco, Inc. accounts for 82.9% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2020 at $39,101 and has fallen 94.6% since, to $2,119 in 2025.
Across 302 payments — averaging $204.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Barco, Inc.$51K
- Regeneron Healthcare Solutions, Inc.$2K
- Solta Medical, A Division Of Bausch Health US, LLC$962
- Johnson & Johnson$789
- Kerecis Limited$605
- Pfizer$521
- plus $6K from 35 others
Across 6 payments — averaging $11,646 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Avita Medical Americas, LLC$70K
What the payments were for
- Consulting fees$47,71177%
- Speaking & faculty fees$5,6529%
- Travel & lodging$3941%
- Food & beverage$7,89413%
- Education$1450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$1,612
- Kerecis SurgiClose$1,578
- RECELL$500
- Kerecis GraftGuide$394
- Clear & Brilliant$363
- ZORYVE$236
- Tremfya$140
- VOQUEZNA$115
- VTAMA$114
How this compares
$61,797 in reported general payments places this provider in the 80th percentile of 73 dermatology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 30 | $1,599 |
| Fluocinonide | 28 | $882 |
| Ketoconazole | 56 | $729 |
| Ciclopirox | 18 | $553 |
| Gentamicin Sulfate | 13 | $465 |
| Minoxidil | 27 | $360 |
| Triamcinolone Acetonide | 22 | $349 |
| Econazole Nitrate | 28 | $312 |
| Cephalexin | 25 | $220 |
| Mupirocin | 16 | $144 |
| ValacyclovirValacyclovir Hcl | 13 | $95 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Washington
- Jonathan SilverbergWashington$4.5M
- Adam FriedmanWashington$2.2M
- Terrence KeaneyWashington$1.1M
- Candrice HeathWashington$168K
- Agnes ChangWashington$109K
- Todd PerkinsWashington$102K
- Karl SaardiWashington$101K
- Noelle SherberWashington$96K
- Yolanda HolmesWashington$80K
- Cheri FreyWashington$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.